VANCOUVER and SAN DIEGO, May 18 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC:
MGIFF), a clinical-stage developer of drugs for infectious diseases will make
a presentation of results from a recent hepatitis C Phase II combination
therapy study (see April 11, 2007 press release) in a non-responder patient
population at Digestive Disease Week (DDW) 2007 being held in Washington, DC
May 19-24, 2007. Dr. Kelly Kaita, the Director of the Viral Hepatitis
Investigative Unit (VHIU) at the Health Sciences Centre, University of
Manitoba and a lead investigator in the MIGENIX Phase II study will make the
presentation.
The presentation entitled: "Phase II Study of Celgosivir in Combination
with Peginterferon alfa-2b and Ribavirin in Chronic Hepatitis C Genotype-1
Non-responder Patients" (Abstract No. 324227) will be made on Monday, May 21,
at 2:45 p.m. (EDT) in Room 206 of the Washington Convention Center.
Additionally on May 20, 2007 Dr. Kaita and AnnKatrin Petersen, M.D., Vice
President, Clinical Development of MIGENIX will participate in a DDW news
conference highlighting progress in new and evolving areas of chronic
hepatitis C therapy including celgosivir. A copy of the presentation and the
related Abstract will be available at www.migenix.com following the
presentation.
Research being presented at Digestive Disease Week 2007 analyzes
advancements in the diagnosis of hepatitis C and therapies available to
patients who suffer from the disease. DDW is the largest international
gathering of physicians and researchers in the fields of gastroenterology,
hepatology, endoscopy and gastrointestinal surgery. Digestive Disease Week is
considered the largest and most prestigious meeting in the world for the
gastrointestinal professional. Every year DDW attracts more than 16,000
physicians, researchers and academics from around the world.
About Celgosivir (MX-3253)
Celgosivir is an oral alpha-glucosidase I inhibitor and is currently the
only anti-HCV drug in clinical development that acts on host-directed
glycosylation. In preclinical studies, celgosivir has shown excellent in vitro
synergy with various interferons in the clinic or in development including
Pegasys, PEG-Intron, Infergen, Alferon and IFN-omega (with or without
ribavirin) and other drugs in development for the treatment of HCV (e.g.
polymerase inhibitors) and therefore has the potential to be included as part
of multiple combination approaches to improve efficacy in anti-HCV therapy.
About MIGENIX
MIGENIX is committed to advancing therapy, improving health, and
enriching life by developing and commercializing drugs primarily in the area
of infectious diseases. The Company's clinical programs include drug
candidates for the treatment of chronic hepatitis C infections (Phase II and
preclinical), the prevention of catheter-related infections (Phase III) and
the treatment of dermatological diseases (Phase II). MIGENIX is headquartered
in Vancouver, British Columbia, Canada with US operations in San Diego,
California. Additional information can be found at www.migenix.com.
"Art Ayres"
-----------
Arthur J. Ayres, CA.
Sr VP Finance & CFO
The Toronto Stock Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
For further information: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666
Ext. 233, aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group,
Tel: (212) 825-3210, Theproteam@aol.com
